Applied StemCell

Executive Summary

Applied StemCell is a privately held biotechnology company specializing in genome engineering and iPSC-based cell therapy development. Founded in 2008 and headquartered in Milpitas, California, the company provides proprietary technologies and services to biopharma clients, with its core TARGATT™ platform enabling precise, large gene knock-ins for allogeneic iPSC therapeutics. By leveraging its iPSC expertise and patented tools, Applied StemCell supports the discovery, development, and manufacturing of advanced cell therapies, positioning itself as a key enabler in the regenerative medicine space. The company's platform addresses critical challenges in cell therapy, such as efficient gene editing and scalable production, making it a strategic partner for both emerging and established biotech firms.

Upcoming Catalysts (preview)

• Q4 2026Announcement of new partnership or licensing deal for iPSC platform60% success
• Q1 2027Publication of preclinical data validating TARGATT platform in disease model50% success
• Q2 2027FDA IND clearance or clinical trial initiation for a partnered candidate30% success